Biosyent (Biosyent) Total Liabilities : $5.05 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Biosyent Total Liabilities?

Biosyent's Total Liabilities for the quarter that ended in Dec. 2023 was $5.05 Mil.

Biosyent's quarterly Total Liabilities increased from Jun. 2023 ($4.85 Mil) to Sep. 2023 ($5.06 Mil) but then declined from Sep. 2023 ($5.06 Mil) to Dec. 2023 ($5.05 Mil).

Biosyent's annual Total Liabilities increased from Dec. 2021 ($4.39 Mil) to Dec. 2022 ($5.24 Mil) but then declined from Dec. 2022 ($5.24 Mil) to Dec. 2023 ($5.05 Mil).

Biosyent Total Liabilities Historical Data

The historical data trend for Biosyent's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Total Liabilities Chart

Biosyent Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.93

5.29

4.39

5.24

5.05

Biosyent Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															5.24	3.90	4.85	5.06	5.05

Biosyent Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biosyent's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.125	+	(0.774	+	-0.0020000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.148	+	0)
	=	5.05

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	30.955	-	25.909
	=	5.05

Biosyent's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.125	+	(0.774	+	-0.0020000000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.148	+	0)
	=	5.05

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	30.955	-	25.909
	=	5.05

Biosyent Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biosyent's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent (Biosyent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RX:Canada

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.